The Role of Microfungi in the Human Gut Microbiota

Snata Pandey

Department of Microbiology

St. Xavier’s College (Autonomous)

Kolkata, India

**ABSTRACT**

The gut mycobiome has recently gained significant attention due to its vast myriad of implied roles. The fungal commensals residing in human guts, in low amounts, are involved in host homeostasis maintenance, digestion, mental balance and immunity. Several antifungals have been seen useful in relieving symptoms of neurological diseases. Dysbiosis of different fungal species is proved in gastric, autoimmune, and psychiatric diseases. A deeper understanding of the nature of dysbiosis involved in immunity and diseases can prove gut fungi to be instrumental in clinical treatments.

Keywords—gut mycobiome; dysbiosis; neurological diseases; microeukaryotes; gastric disorders; immunity

# I. INTRODUCTION

Microbes, both beneficial and harmful, which reside as communities all over our bodies are collectively called the human microbiome. Specifically in the gut, bacteria, archaea, protists, viruses, and fungi colonize to form an essential ecosystem [1], called the gut microbiota. The fungi here are termed as the gut mycobiome [2]. A fungus-free existence is both implausible and undesirable. Gut microbial studies have primarily focused on gut bacteria until very recently, due to the larger quantity of the bacteriobiome, and the sole and limiting prominence of culture-dependent methods of studying fungi. Techniques like polymerase chain reaction and next generation sequencing are now helping DNA-based detection of this less studied diversity of fungal communities of the human gut. This is crucial, because fungi occur as commensals as a part of our holobiomes and are crucial in maintaining the ecology in our guts along with the other gut communities. They do not live isolated, they interact extensively and benefit the host, provided they occur in low amounts. This multi-kingdom diversity and interplay of gut microbes is fundamental in maintenance of health and homeostasis of the host and their dysbiosis has been linked to several diseases [1], including the Inflammatory Bowel Diseases [3], diabetes [4, 5] and cancer [6]. It is also clear now that fungi in the gut act as “intestinal vaccines”. The potential of utilizing fungal metabolites in clinical applications is being examined.

# II. GENERAL COMPOSITION AND INTERKINGDOM INTERACTIONS

By far, fungi occupy less than 0.1% of the total human gut microbiome (by genomic equivalence) [7]. The members of the phylum Ascomycota, and fewer members from phyla Zygomycota and Basidiomycota are prevalent. The most predominant genera in the intestinal niche are the *Malassezia, Candida*, and *Saccharomyces* [8], although there also occur *Cryptococcus, Aspergillus, Cladosporium, Fusarium, Penicillium, Pichia, Trichosporon* etc [9]. The composition varies between humans, genders, and ages, the reason behind which is not apparent. It is hypothesized that distinct colonization early in life from mother during birth and different environmental exposures such as antibiotic use and diet bring about such diversity among individuals. Infants have the most dynamic communities, where all carry *C. albicans*, although the fewer number of fungi in infants is probably because they are yet to be fully colonized [10]. Healthy females have higher fungal diversity than healthy males [10].

Yeasts, discovered in stool samples in the early 20th century, were considered to be saprotrophs in the intestines of humans. *Candida albicans*, at its colonization levels (1-2% of the total fungal count), interacts with the archaea M*ethanobrevibacter*to ingest carbohydrates in our diet [11]. *Saccharomyces* and *Pichia* can independently help to keep *Candida* number under control within the commensal level, since increase in their number would lead to diseases. Fungi can also participate in forming ‘mixed species biofilms’, characteristic of different diseases including Crohn’s disease [12], which enable the different communities involved to remain more protected and grow better [10].

# III. RELEVANCE OF GUT MYCOBIOME IN DISEASES

## **Role in Gut-Brain Axis and Neurological Diseases**

Several clinical and experimental evidences for the role of fungi in the gut-brain axis can be seen. Sterilized animals show increased blood-brain barrier permeability, changes in the myelin sheath and anxiety-depressive behaviours [13]. The fungal diversity of anorexic patients showed certain species of fungi including *Aspergillus ruber, Penicillium solitum, and Cladosporium bruhnei* which were previously not found in healthy humans [14].

Autism Spectrum Disorder patients showed a trend in increased abundance of Candida and *Saccharomyces* and *Aspergillus* at the genus levels and a decreased abundance in *Aspergillus versicolor* was observed while *Saccharomyces cerevisiae* was increased in children out of 507 studied species controlled to control [15]. Patients with Rett Syndrome showed elevated *Candida* levels [16].

Schizophrenic patients showed increased quantities of C. albicans and S. cerevisiae [17]. Psychiatric symptoms were improved using probiotics with Lactobacillus rhamnosus and Bifidobacterium animalis, which essentially reduced *C. albicans* levels in the blood as a remedy [18]. On sequencing fungal rRNA ITS1 gene from Alzheimer’s patients, certain families of fungi were notably higher in amount, and the specific genera *Botrytis, Kazachstania, Phaeoacremonium* and *Cladosporium* were abundant compared to healthy individuals, and the patients’ mycobiome were associated with diet, bacteriobiome and AD markers [19].

# Role in Gastric Disorders and Cancers

Gut fungi were seen involved closely with the Inflammatory Bowel Diseases (IBD). There are two IBDs, Crohn's disease (CD) and ulcerative colitis (UC). IBD-affected individuals carry greater quantities of fungi in their guts. *Candida tropicalis*, *E. coli* and *Serratia marcescens* increase in Crohn’s disease patients, which interact and stick together to form digestive plaques (mixed-species biofilms) [12]. IBD patients’ guts are also found to have, at the phylum level, a significantly increased Basidiomycota to Ascomycota ratio; at the genus level, *Candida* increases while *Saccharomyces* decreases [20]. *Malassezia* levels are seen to rise in IBD patients, with UC patients specifically showing negative correlation between *Malassezia* and bacteria; the association between *Malassezia* and IBD may be attributed to aryl hydrocarbon receptor [21].

Gut mycobiome may be closely related to the pathogenesis of irritable bowel syndrome [22]. In rats with induced gut fungal dysbiosis showed visceral hypersensitivity, which is typical in rats affected by in IBS [23]. In IBS, an increase in Kazachstania turicensis, Monographella nivalis, Alternaria alternata, and Davidiella tassiana may be used as biomarkers [23]. Saccharomyces *boulardii* substitutions improved symptoms in IBS-affected rats [24]. Different fungi also cause typical symptoms of UC, such as Zygosaccharomyces causing abdominal pain and Candida positively correlating with bloating [25].

With respect to tumor formation, gut fungi were seen to displace to the pancreas, particularly, Malassezia spp. filled up pancreatic tumors [6]. A C3 protein is triggered by mannose binding lectin due to the binding with an unidentified carbohydrate structure on *Malassezia*, resulting into a complement cascade and tumour formation in the pancreas [6]. Gut fungal dysbiosis has also been implicated in colorectal cancer [26].

# IV. GUT MYCOBIOME IN INNATE IMMUNITY AND THERAPEUTICS

It was seen that healthy individuals with no history of a fungal infection carried antifungal antibodies in their bloodstream, which prevented infections from several pathogenic fungal species [27]. Immunocompromised individuals, on the other hand, carried declined quantities of such antifungal antibodies, rendering them susceptible to fungal infections [27]. When purified antibodies were injected into the patients, they fought the common infections better [27]. This indicated the role of the commensal intestinal fungi, like *Candida*, as an “intestinal vaccine” against fungal infections. Furthermore, the CARD9 gene is seen in its wild-type form in healthy individuals with antifungal antibodies, while a mutated form is seen in patients without the antibodies [27]. At the same time, intestinal fungi like *Candida* and *Saccharomyces* can effectively replace bacteria in case of enteric bacteria eradication, and with their mannans play a protective role against viral diseases and colitis [28]. Fecal Microbiota Transplant is showing potential in treating several diseases, as also to prevent their relapses. Interestingly, in performing FMT in patients with Ulcerative Colitis, those with higher levels of *Candida* prior to the procedure showed better responses, and the transplant then acted to decrease the population of *Candida* [29]. Possible strategies targeted at the gut mycobiome for managing inflammatory bowel diseases will now have to be explored [30].

Antifungals have shown an interesting use in neurological diseases, like miconazole being used for MS treatment [31], and antifungal therapy using fluconazole is now widely used for individuals with ASD. [Fungal vaccine](https://www.sciencedirect.com/topics/medicine-and-dentistry/fungus-vaccine) development has been proposed as one of the treatments and prevention strategies in the last decade, which is why fungal vaccines are under research although none has yet been approved.

# V. CONCLUSION

Despite constituting a minor portion of the gut microbiome, gut fungal dysbiosis introduces the risk for several diseases in the gastrointestinal tract, anxiety-depressive behaviours, diabetes, cancers etc. Maintenance of a healthy gut ecosystem is thus proven excessively crucial. Research is now being conducted to identify the exact genera and species involved in each, so that a focused treatment method for such diseases can be established.

##### REFERENCES

1. V. K. Chin, V. C. Yong, P. P. Chong, S. Amin Nordin, R. Basir, M. Abdullah, “Mycobiome in the gut: a multiperspective review,” Mediators Inflamm. 2020 Apr 4;2020:9560684. doi: 10.1155/2020/9560684.
2. P. M. Gillevet, M. Sikaroodi, A. P. Torzilli, “Analyzing salt-marsh fungal diversity: comparing ARISA fingerprinting with clone sequencing and pyrosequencing,” *Fungal Ecology*, vol. 2, no. 4, Nov. 2009, pp. 160–67. doi: [10.1016/j.funeco.2009.04.001](http://dx.doi.org/10.1016/j.funeco.2009.04.001)
3. M. L. Richard, B. Lamas, G. Liguori, T. W. Hoffmann, H. Sokol, “Gut fungal microbiota: the Yin and Yang of inflammatory bowel disease,” Inflamm Bowel Dis. 2015 Mar;21(3):656-65. doi: 10.1097/MIB.0000000000000261.
4. D. Salamon, et al., “Analysis of the gut mycobiome in adult patients with type 1 and type 2 diabetes using Next-Generation Sequencing (NGS) with increased sensitivity-pilot study,” Nutrients. 2021 Mar 25;13(4):1066. doi: 10.3390/nu13041066.
5. E. V. Syoc, et al., “Changes in the gut mycobiome are associated with Type 2 diabetes mellitus and metformin treatment across populations,” bioRxiv. 2023 May 25:2023.05.25.542255. doi: 10.1101/2023.05.25.542255., preprint.
6. J. R. Galloway-Peña and D. P. Kontoyiannis, “The gut mycobiome: the overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions,” *PLOS Pathogens*, vol. 16, no. 4, Apr. 2020, p. e1008353. [doi: 10.1371/journal.ppat.1008353](https://doi.org/10.1371/journal.ppat.1008353).
7. J. Qin, et al. “A human gut microbial gene catalogue established by metagenomic sequencing,” *Nature*, vol. 464, no. 7285, Mar. 2010, pp. 59–65. doi: 10.1038/nature08821.
8. A. K. Nash, et al. “The gut mycobiome of the Human Microbiome Project healthy cohort,” *Microbiome*, vol. 5, no. 1, Nov. 2017, p. 153. doi: 10.1186/s40168-017-0373-4
9. H. E. Hallen-Adams, S. D. Kachman, J. Kim, R. M. Legge, and I. Martínez, “Fungi inhabiting the healthy human gastrointestinal tract: a diverse and dynamic community,” *Fungal Ecology*, vol. 15, June 2015, pp. 9–17. [doi: 10.1016/j.funeco.2015.01.006](https://doi.org/10.1016/j.funeco.2015.01.006).
10. C. E. Huseyin, P. W. O’Toole, P. D. Cotter, P. D. Scanlan, “Forgotten fungi—the gut mycobiome in human health and disease,” *FEMS Microbiology Reviews*, vol. 41, no. 4, July 2017, pp. 479–511. doi:[10.1093/femsre/fuw047](https://doi.org/10.1093/femsre/fuw047).
11. C. Hoffmann, et al., “Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents,” *PLoS ONE*, edited by Chongle Pan, vol. 8, no. 6, June 2013, p. e66019. doi: 10.1371/journal.pone.0066019.
12. G. Hoarau, et al., “Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn’s disease,” *mBio*, edited by Robert A. Bonomo, vol. 7, no. 5, Nov. 2016, pp. e01250-16. doi: [10.1128/mBio.01250-16](https://doi.org/10.1128/mBio.01250-16).
13. A. Rutsch, J. K[antsjö](https://www.frontiersin.org/people/u/865870), F. Ronchi, “The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology,” *Frontiers in Immunology*, vol. 11, 2020. doi:[10.3389/fimmu.2020.604179](https://doi.org/10.3389/fimmu.2020.604179)
14. N. Gouba, D. Raoult, M. Drancourt, “Gut microeukaryotes during anorexia nervosa: a case report,” *BMC Research Notes*, vol. 7, no. 1, Jan. 2014, p. 33. doi: 10.1186/1756-0500-7-33
15. R. Zou, et al., “Dysbiosis of Gut Fungal Microbiota in Children with Autism Spectrum Disorders,” *Journal of Autism and Developmental Disorders*, vol. 51, no. 1, Jan. 2021, pp. 267–75. doi: [10.1007/s10803-020-04543-y](https://doi.org/10.1007/s10803-020-04543-y).
16. F. Strati, et al., “Intestinal Candida parapsilosis isolates from Rett syndrome subjects bear potential virulent traits and capacity to persist within the host,” *BMC Gastroenterology*, vol. 18, May 2018, p. 57. doi: [10.1186/s12876-018-0785-z](https://doi.org/10.1186/s12876-018-0785-z).
17. E. Severance, et al., “Gastrointestinal inflammation and associated immune activation in schizophrenia,” *Schizophrenia Research*, vol. 138, no. 1, June 2012, pp. 48–53. doi: [10.1016/j.schres.2012.02.025](https://doi.org/10.1016/j.schres.2012.02.025).
18. E. Severance, et al., “Probiotic normalization of Candida albicans in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study,” *Brain, Behavior, and Immunity*, vol. 62, May 2017, pp. 41–45. doi: [10.1016/j.bbi.2016.11.019](https://doi.org/10.1016/j.bbi.2016.11.019).
19. R. Nagpal, et al., “Gut mycobiome and its interaction with diet, gut bacteria and Alzheimer's disease markers in subjects with mild cognitive impairment: a pilot study,” *eBioMedicine*, vol. 59, Sept. 2020, p. 102950. doi: 10.1016/j.ebiom.2020.102950.
20. E. Mahmoudi, S. Mozhgani, N. Sharifinejad, “The role of mycobiota-genotype association in inflammatory bowel diseases: a narrative review,” *Gut Pathogens*, vol. 13, May 2021, p. 31. doi: [10.1186/s13099-021-00426-4](https://doi.org/10.1186/s13099-021-00426-4).
21. M. Spatz and R. Mathias, “Overview of the potential role of *Malassezia* in gut health and disease,” *Frontiers in Cellular and Infection Microbiology*, vol. 10, 2020. doi: [10.3389/fcimb.2020.00201](https://www.frontiersin.org/articles/10.3389/fcimb.2020.00201).
22. Y. Gu, et al., “The potential role of gut mycobiome in irritable bowel syndrome,” *Frontiers in Microbiology*, vol. 10, 2019. doi:10.3389/fmicb.2019.01894.
23. S. Botschuijver, et al., “Intestinal fungal dysbiosis is associated with visceral hypersensitivity in patients with irritable bowel syndrome and rats,” *Gastroenterology*, vol. 153, no. 4, Oct. 2017, pp. 1026–39. doi:[10.1053/j.gastro.2017.06.004](https://doi.org/10.1053/j.gastro.2017.06.004).
24. J. Liu, H. Ren, F. Yuan, M. Shao, H. Luo, “The effects of Saccharomyces boulardii on rat colonic hypermotility induced by repeated water avoidance stress and the potential mechanism,” *PeerJ*, vol. 10, Nov. 2022, p. e14390. doi: 10.7717/peerj.14390.
25. Hong, G., et al. “Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: an explorative study,” *Neurogastroenterology & Motility*, vol. 32, no. 11, Nov. 2020. doi: 10.1111/nmo.13891.
26. O. Coker, et al., “Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer,” *Gut*, vol. 68, no. 4, Apr. 2019, pp. 654–62. doi: 10.1136/gutjnl-2018-317178.
27. I. Doron, et al., “Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies,” *Cell*, vol. 184, no. 4, Feb. 2021, pp. 1017-1031.e14. doi: [10.1016/j.cell.2021.01.016](https://doi.org/10.1016/j.cell.2021.01.016).
28. T. T. Jiang, et al., “Commensal fungi recapitulate the protective benefits of intestinal bacteria,” *Cell Host & Microbe*, vol. 22, no. 6, Dec. 2017, pp. 809-816.e4. doi:10.1016/j.chom.2017.10.013.
29. I. Leonardi, et al., “Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis.” *Cell Host & Microbe*, vol. 27, no. 5, May 2020, pp. 823-829.e3. [doi: 10.1016/j.chom.2020.03.006](https://doi.org/10.1016/j.chom.2020.03.006).
30. S. Lam, et al., “Roles of the gut virome and mycobiome in faecal microbiota transplantation,” *The Lancet Gastroenterology & Hepatology*, vol. 7, no. 5, May 2022, pp. 472–84. doi: 10.1016/S2468-1253(21)00303-4.
31. F. Najm, et al., “Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo,” *Nature*, vol. 522, no. 7555, June 2015, pp. 216–20. [doi: 10.1038/nature14335](https://doi.org/10.1038/nature14335).